Fig. 8: Comprehensive serine/threonine/tyrosine phosphoproteomics confirm EGFR1 pathway involvement in TgErbB2 hypertrophy and tyrosine kinase receptor inhibition by AG-825. | Communications Biology

Fig. 8: Comprehensive serine/threonine/tyrosine phosphoproteomics confirm EGFR1 pathway involvement in TgErbB2 hypertrophy and tyrosine kinase receptor inhibition by AG-825.

From: Alteration in tyrosine phosphorylation of cardiac proteome and EGFR pathway contribute to hypertrophic cardiomyopathy

Fig. 8

a A heatmap was used to visualize the unsupervised hierarchical clustering of Ser/Thr peptides, and b pTyrosine peptides normalized to full proteome expression with p-value < 0.05 by ANOVA. Overrepresented (yellow) and underrepresented (Blue). c Volcano plots showing the Log2 fold-change and –Log10 p-value of each pSer/pThr peptide and d pTyr peptides in the pairwise comparison of Ntg and TgErbB2 after two weeks of Vehicle Treatment. e Volcano plots showing the Log2 fold-change and –Log10 p-value of each pSer/pThr peptide and f pTyr peptides in the pairwise comparison of Ntg and TgErbB2 after two weeks of AG-825 Treatment, (g) KSEA shows in a red rectangle the kinases significantly inhibited by AG-825. KSEA and Pathway Enrichment Analysis of combined Ser/Thr/Tyr phosphorylation data analysis using PTMSigDB confirm that EGFR1 Pathway is significantly involved. h The Signaling Network Open Resource (Signor 2.0) analysis shows that nine kinases are involved in the EGFR pathway. Kinases found in the network and also in KSEA are circled in dotted blue circles. The symbol code of the network is displayed next to the pathway.

Back to article page